Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 11/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23387366 | 0.89 | TRPV1 (0.47) | CHRM4CHRM2CHRM1 | |
| SCHEMBL27233738 | 0.89 | TRPV1 (0.47) | CHRM4CHRM2CHRM1 | |
| SCHEMBL23387368 | 0.89 | TRPV1 (0.47) | CHRM4CHRM2CHRM1 | |
| SCHEMBL27173030 | 0.86 | CHRM2 (0.45) | CHRM4CHRM2ACACBCHRM1 | |
| SCHEMBL19754737 | 0.81 | CHRM4 (0.49) | CHRM4CHRM2ACACB | |
| SCHEMBL16433993 | 0.80 | NOTUM (0.49) | CHRM4CHRM2ACACBHDAC3HDAC4 | |
| SCHEMBL2004487 | 0.79 | GRM4 (0.61) | — | |
| SCHEMBL20283121 | 0.78 | CHRM4 (0.47) | CHRM4CHRM2ACACBHDAC3HDAC4 | |
| SCHEMBL16433994 | 0.78 | ACACB (0.50) | CHRM4CHRM2ACACBHDAC3HDAC4 | |
| SCHEMBL23297073 | 0.78 | CHRM2 (0.42) | CHRM4CHRM2ACACBCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| US-20230348490-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-4186910-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230014109-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-01-19 | — | — | US | disclosed |
| US-11142532-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-20190161498-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2019-05-30 | — | — | US | disclosed |
| EP-3474846-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10239887-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2018035444-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2017223290-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170369505-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014109-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | CHRM4 1/4885CHRM2 3/4885ACACB 2811/4885 |
| US-20230348490-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | CHRM4 1/4885CHRM2 3/4885ACACB 2811/4885 |
| US-11142532-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM5, CHRM2 | CHRM4 1/4885CHRM2 3/4885ACACB 2811/4885 |
| US-20190161498-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | CHRM4 1/4885CHRM2 3/4885ACACB 2811/4885 |
| US-20170369505-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | CHRM4 1/4885CHRM2 3/4885ACACB 2811/4885 |
| US-10239887-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM5, CHRM2 | CHRM4 1/4885CHRM2 3/4885ACACB 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.